PT - JOURNAL ARTICLE AU - Jensen, Matthew AU - Smolen, Corrine AU - Tyryshkina, Anastasia AU - Pizzo, Lucilla AU - Banerjee, Deepro AU - Oetjens, Matthew AU - Shimelis, Hermela AU - Taylor, Cora M. AU - Pounraja, Vijay Kumar AU - Song, Hyebin AU - Rohan, Laura AU - Huber, Emily AU - El Khattabi, Laila AU - van de Laar, Ingrid AU - Tadros, Rafik AU - Bezzina, Connie AU - van Slegtenhorst, Marjon AU - Kammeraad, Janneke AU - Prontera, Paolo AU - Caberg, Jean-Hubert AU - Fraser, Harry AU - Banka, Siddhartha AU - Van Dijck, Anke AU - Schwartz, Charles AU - Voorhoeve, Els AU - Callier, Patrick AU - Mosca-Boidron, Anne-Laure AU - Marle, Nathalie AU - Lefebvre, Mathilde AU - Pope, Kate AU - Snell, Penny AU - Boys, Amber AU - Lockhart, Paul J. AU - Ashfaq, Myla AU - McCready, Elizabeth AU - Nowacyzk, Margaret AU - Castiglia, Lucia AU - Galesi, Ornella AU - Avola, Emanuela AU - Mattina, Teresa AU - Fichera, Marco AU - Bruccheri, Maria Grazia AU - Mandarà, Giuseppa Maria Luana AU - Mari, Francesca AU - Privitera, Flavia AU - Longo, Ilaria AU - Curró, Aurora AU - Renieri, Alessandra AU - Keren, Boris AU - Charles, Perrine AU - Cuinat, Silvestre AU - Nizon, Mathilde AU - Pichon, Olivier AU - Bénéteau, Claire AU - Stoeva, Radka AU - Martin-Coignard, Dominique AU - Blesson, Sophia AU - Le Caignec, Cedric AU - Mercier, Sandra AU - Vincent, Marie AU - Martin, Christa AU - Mannik, Katrin AU - Reymond, Alexandre AU - Faivre, Laurence AU - Sistermans, Erik AU - Kooy, R. Frank AU - Amor, David J. AU - Romano, Corrado AU - Andrieux, Joris AU - Girirajan, Santhosh TI - Genetic modifiers and ascertainment drive variable expressivity of complex disorders AID - 10.1101/2024.08.27.24312158 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.27.24312158 4099 - http://medrxiv.org/content/early/2024/08/28/2024.08.27.24312158.short 4100 - http://medrxiv.org/content/early/2024/08/28/2024.08.27.24312158.full AB - Variable expressivity of disease-associated variants implies a role for secondary variants that modify clinical features. We assessed the effects of modifier variants towards clinical outcomes of 2,252 individuals with primary variants. Among 132 families with the 16p12.1 deletion, distinct rare and common variant classes conferred risk for specific developmental features, including short tandem repeats for neurological defects and SNVs for microcephaly, while additional disease-associated variants conferred multiple genetic diagnoses. Within disease and population cohorts of 773 individuals with the 16p12.1 deletion, we found opposing effects of secondary variants towards clinical features across ascertainments. Additional analysis of 1,479 probands with other primary variants, such as 16p11.2 deletion and CHD8 variants, and 1,084 without primary variants, showed that phenotypic associations differed by primary variant context and were influenced by synergistic interactions between primary and secondary variants. Our study provides a paradigm to dissect the genomic architecture of complex disorders towards personalized treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by NIH R01-GM121907 and resources from the Huck Institutes of the Life Sciences to S.G. M.J. and C.S. were supported by NIH T32-GM102057. A.T. was supported by NIH T32-LM012415. L.P. was supported by Fulbright Commission Uruguay-ANII. A.R. was supported by grants from the Swiss National Science Foundation 31003A_182632. S.B. was supported by the NIHR Manchester Biomedical Research Centre (NIHR203308).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards of Pennsylvania State University and Geisinger Health Systems gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesWhole genome sequencing and SNP microarray data generated in this study are available at NCBI dbGaP phs002450.v2.p1. Statistical analyses and experimental results for the data presented in Figs. 2-7 and associated supplementary figures are available in Tables S2-S6.  https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002450.v2.p1 https://github.com/girirajanlab/16p12_WGS_project